心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2014年
3期
287-291
,共5页
冠状血管痉挛%治疗结果%地尔硫卓
冠狀血管痙攣%治療結果%地爾硫卓
관상혈관경련%치료결과%지이류탁
Coronary vasospasm%Treatment outcome%Diltiazem
目的：探讨地尔硫卓治疗冠脉痉挛的临床疗效及安全性。方法：选择我院的100例冠脉痉挛患者，按照抽签法随机均分为：常规治疗组（50例，予以调脂、扩冠等常规治疗）；地尔硫卓组（50例，在常规治疗基础上泵入地尔硫卓），比较两组临床、心电图疗效及治疗前后一氧化氮（NO），内皮素-1（ET-1）水平等的变化和安全性。结果：（1）与常规治疗组比较，地尔硫卓组临床治疗总有效率（60.00％比94.00％）、心电图总疗效（62.00％比92.00％）显著提高（P均＜0.01）；（2）两组治疗后心电图各项指标、心率、血压均较治疗前明显改善，且地尔硫卓组较常规治疗组改善更显著（P均＜0.05）；（3）地尔硫卓组治疗后血脂水平较治疗前及常规组治疗后有明显改善（P均＜0.05）；（4）与治疗前及常规治疗组比较，治疗后地尔硫卓组 NO 水平[（95.17±19.99）μmol/L、（95.17±21.22）μmol/L比（106.71±22.38）μmol/L]显著升高、ET-1水平[（64.09±16.29）ng/L、（59.98±14.28）ng/L比（44.91±6.38）ng/L]显著降低（P均＜0.05）；（6）两组治疗过程中，均未出现任何不良反应。结论：在常规药物治疗的基础上加用地尔硫卓治疗冠脉痉挛，疗效显著，安全性高，值得推广。
目的：探討地爾硫卓治療冠脈痙攣的臨床療效及安全性。方法：選擇我院的100例冠脈痙攣患者，按照抽籤法隨機均分為：常規治療組（50例，予以調脂、擴冠等常規治療）；地爾硫卓組（50例，在常規治療基礎上泵入地爾硫卓），比較兩組臨床、心電圖療效及治療前後一氧化氮（NO），內皮素-1（ET-1）水平等的變化和安全性。結果：（1）與常規治療組比較，地爾硫卓組臨床治療總有效率（60.00％比94.00％）、心電圖總療效（62.00％比92.00％）顯著提高（P均＜0.01）；（2）兩組治療後心電圖各項指標、心率、血壓均較治療前明顯改善，且地爾硫卓組較常規治療組改善更顯著（P均＜0.05）；（3）地爾硫卓組治療後血脂水平較治療前及常規組治療後有明顯改善（P均＜0.05）；（4）與治療前及常規治療組比較，治療後地爾硫卓組 NO 水平[（95.17±19.99）μmol/L、（95.17±21.22）μmol/L比（106.71±22.38）μmol/L]顯著升高、ET-1水平[（64.09±16.29）ng/L、（59.98±14.28）ng/L比（44.91±6.38）ng/L]顯著降低（P均＜0.05）；（6）兩組治療過程中，均未齣現任何不良反應。結論：在常規藥物治療的基礎上加用地爾硫卓治療冠脈痙攣，療效顯著，安全性高，值得推廣。
목적：탐토지이류탁치료관맥경련적림상료효급안전성。방법：선택아원적100례관맥경련환자，안조추첨법수궤균분위：상규치료조（50례，여이조지、확관등상규치료）；지이류탁조（50례，재상규치료기출상빙입지이류탁），비교량조림상、심전도료효급치료전후일양화담（NO），내피소-1（ET-1）수평등적변화화안전성。결과：（1）여상규치료조비교，지이류탁조림상치료총유효솔（60.00％비94.00％）、심전도총료효（62.00％비92.00％）현저제고（P균＜0.01）；（2）량조치료후심전도각항지표、심솔、혈압균교치료전명현개선，차지이류탁조교상규치료조개선경현저（P균＜0.05）；（3）지이류탁조치료후혈지수평교치료전급상규조치료후유명현개선（P균＜0.05）；（4）여치료전급상규치료조비교，치료후지이류탁조 NO 수평[（95.17±19.99）μmol/L、（95.17±21.22）μmol/L비（106.71±22.38）μmol/L]현저승고、ET-1수평[（64.09±16.29）ng/L、（59.98±14.28）ng/L비（44.91±6.38）ng/L]현저강저（P균＜0.05）；（6）량조치료과정중，균미출현임하불량반응。결론：재상규약물치료적기출상가용지이류탁치료관맥경련，료효현저，안전성고，치득추엄。
Objective:To explore clinical therapeutic effect and safety of diltiazem treating coronary artery spasm. Methods:A total of 100 patients with coronary artery spasm were selected in our hospital.According to number ta-ble method,they were randomly and equally divided into routine treatment group (n=50,received,lipid regulation and expanding coronory artery etc.)and diltiazem group (n=50,received diltiazem pumping based on routine treat-ment).Clinical and ECG therapeutic effect,changes of blood lipids,nitric oxide (NO)and endothelin-1 (ET-1) levels before and after treatment and safety were compared between two groups.Results:(1 )Compared with rou-tine treatment group,there were significant increase in total effective rates of clinical effect (60.00% vs.94.00%) and ECG (62.00% vs.92.00%)in diltiazem group,P<0.01 both;(2)Compared with before treatment,there were significant improvements in all ECG indexes,heart rate and blood pressure in two groups after treatment,and those of diltiazem group were significantly better than those of routine treatment group (P<0.05 all);(3)Com-pared with before treatment and routine treatment group,there were significant improvements in blood lipid levels in diltiazem group after treatment (P<0.05 all);(4)Compared with before treatment and routine treatment group,there was significant rise in NO level [(95.17±19.99)μmol/L,(95.17±21.22)μmol/L vs.(106.71± 22.38)μmol/L]and significant reduction in ET-1 level [(64.09±16.29)ng/L,(59.98±14.28)ng/L vs.(44.91± 6.38)ng/L]in diltiazem group after treatment (P<0.05 all);(6)During treatment,there were no adverse reac-tion in both groups.Conclusion:Diltiazem based on routine medication possess significant therapeutic effect and high safety for treating coronary artery spasm,which is worth extension in clinic.
